News

Everything You Need to Know Before Levi Strauss's Earnings

Everything You Need to Know Before Levi Strauss's Earnings

An Overview of Levi Strauss's Earnings Outlook

Levi Strauss (NYSE: LEVI) is set to reveal its quarterly earnings soon, creating a buzz among investors who are keen to gain insights into the company's performance. What should investors keep in mind before this important announcement? Let's break it down.

Analysts are projecting that Levi Strauss will report an earnings per share (EPS) of $0.31. This figure has created an air of anticipation as many hope that the company will not only meet but exceed these estimates, providing a positive outlook for the next quarter.

For new investors, it is crucial to recognize that while achieving strong earnings is noteworthy, the guidance provided by the company can often sway market reactions more significantly. Therefore, paying attention to the overall context surrounding the earnings report is essential.

A Glance at Historical Earnings

In the last quarter, Levi Strauss managed to outperform expectations with an EPS of $0.36, beating estimates by $0.05. However, this good news didn't translate into stock gains, as the share price plummeted by 15.4% the following day.

Current Stock Performance Status

As of September 30, shares of Levi Strauss were trading at $21.80, marking a 60.54% increase over the past year. This impressive performance has likely instilled optimism among long-term shareholders who anticipate a positive earnings release.

Insights from Analysts on Levi Strauss

In the competitive retail landscape, staying ahead of market sentiments is vital for investors. For Levi Strauss, the consensus rating from analysts is “Buy,” backed by two positive ratings. The average target price set by analysts is $25.50, suggesting a potential upside of about 16.97% from the current trading price.

Comparative Ratings with Industry Peers

Comparing Levi Strauss's performance with competitors Amer Sports, VF Corporation, and Tapestry can provide deeper insights into its market standing. Here’s a look at some key ratings:

  • Amer Sports has maintained a Buy status, with a target price of $19, indicating a potential downside of 12.84%.
  • VF Corporation is rated Neutral, with an average target of $16.32, which suggests a more concerning potential downside of 25.14%.
  • Tapestry is rated Outperform, with a target of $49.62, indicating a remarkable potential upside of 127.61%.

Summary of Peer Analysis

A peer analysis sheds light on several essential metrics for these companies, highlighting their respective market positions. Such analyses are key for understanding where Levi Strauss fits within this competitive framework.

For example, Levi Strauss tops its peers in revenue growth, boasting an impressive rate of 7.81%. This achievement puts it ahead in terms of financial health, although its return on equity remains relatively low compared to others.

Getting to Know Levi Strauss Better

Levi Strauss & Co. specializes in designing and selling a diverse array of apparel, including jeans, casual wear, and various accessories for men, women, and children. The brand operates under well-known labels such as Levi's and Dockers, servicing consumers through both direct sales and partnerships.

The Economic Impact of Levi Strauss

Market Capitalization: The company’s market capitalization reflects substantial size, indicating robust market acknowledgment above average industry levels.

Revenue Growth Trends: Recent financial analyses suggest a promising trajectory for Levi Strauss. The company reported a revenue growth of 7.81% just last month, outpacing many competitors in the Consumer Discretionary sector.

Net Margin Details: The company’s net margin stands at 1.25%, which is competitive within the industry, demonstrating effective cost management and profitability.

Return on Equity (ROE): Levi Strauss displays impressive ROE of 0.92%, illustrating potent utilization of equity capital and sustainable profitability.

Effective Debt Management: With a captured debt-to-equity ratio of 1.12, the company's reliance on debt remains manageable, suggesting a balanced approach favorably viewed by investors.

Frequently Asked Questions

What is the anticipated EPS for Levi Strauss?

The anticipated earnings per share (EPS) for Levi Strauss is $0.31.

What was the stock performance before the earnings announcement?

Levi Strauss shares were trading at $21.80 as of September 30, reflecting a 60.54% increase over the last year.

How do analysts rate Levi Strauss?

The consensus among analysts is a “Buy” rating for Levi Strauss.

What is Levi Strauss's market capitalization?

Levi Strauss has a substantial market capitalization that stands out above industry averages, reflecting its sizable market presence.

What recent revenue trends have been reported?

The latest reports indicate a revenue growth of 7.81% over the past three months, signaling a positive financial trajectory.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 145

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Swanson Nexus Pro Launch: Boost for Dietitians

Updated Category News Views 213

Swanson Enters the Education Arena for Nutritionists Swanson Vitamins is mixing things up again! This time, they're launching something called Swanson Vitamins Nexus Pro, aimed squarely at the registered dietitians and licensed nutritionists crowd. Starting out as the place to grab your basic vitamins, Swanson's not resting on their supplement laurels. No, siree. They've...

Continue Reading
CapCut's Role in AI-Assisted Small Biz Marketing

Updated Category News Views 25

In today's fast-paced digital world, small businesses lament the constant hustle to stay relevant online. This juggling act with limited resources often makes effective marketing feel like a high-wire circus performance. Enter AI tools, promising to lighten the load, and CapCut stands out as a game-changer. AI Tools Revolutionizing Small Business Marketing Amid growing...

Continue Reading
Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Updated Category News Views 106

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Continue Reading
ASTS Faces Crucial Deadline Amidst Legal Turmoil

Updated Category News Views 208

Ah, the ticking clock in the world of stock investments, where a nifty little thing called a class action lawsuit can flip your investment on its head. Right now, AST SpaceMobile (NASDAQ: ASTS) investors are staring down the barrel of one such lawsuit. With the November 13, 2026, deadline looming, it's time to sort the facts from the muck. Pins and Needles for ASTS...

Continue Reading
Master Sommeliers and Italian Producers Clash on Wine Lists

Updated Category News Views 166

Wines Jockeying for New York’s Coveted Lists Alright, picture a stage set up in New York City like an arena. But instead of gladiators, you've got master sommeliers on one side and Italian wine producers on the other, each armed with their own arguments. They're locked in a battle over what it really takes to get a bottle imbedded on a New York City's prestigious wine...

Continue Reading
World Young Scientist Summit 2026 in Wenzhou Kicks Off

Updated Category News Views 231

Young Minds Meet AI Innovation Crack open the playbook, and it's clear: young brains from across the globe are gathering in Wenzhou, Zhejiang, China, to wrangle with AI and chart the course of science toward a sustainable future. The World Young Scientist Summit 2026 isn't just a parade of speeches and accolades. Nah, it's a deep dive into where innovative minds believe...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 266

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading
CSTS Unveils PremierX in NYC: A Bold Entertainment Move

Updated Category News Views 270

Welcome to the New Era of Entertainment Out of the blockbusters and into the open air, eh? On October 30, 2026, CSTS Enterprises flipped the New York skyline into a canvas for their grand kickoff of PremierXTM—a live entertainment brand poised to redefine how we gobble up our music, sport, and art. Now, there's a shot of adrenaline New Yorkers weren't exactly begging...

Continue Reading
Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Updated Category News Views 48

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Continue Reading

Top 5 Most Recently Viewed Articles

Discover How Indovinya's Innovations Boost Sustainable Agriculture

Updated Category News Views 93

Unlocking the Potential of Biopesticides in Agriculture Indovinya introduces innovative solutions to enhance the use of biologically based products amidst a growing drive for sustainable crop protection. Advancements in Biopesticide Utilization The adoption of biopesticides as an alternative to traditional agrochemicals is gaining traction. However, the integration of...

Continue Reading
SCHMID Group Expands Influence with New Equipment Orders

Updated Category News Views 155

SCHMID Group Strengthens Market Position with New Orders In an exciting development from the SCHMID Group, a key player in the equipment manufacturing sector, the company has recently secured significant orders for Panel Level Packaging (PLP) and modified Semi-Additive (mSAP) production equipment. The orders mark a noteworthy advance as SCHMID continues to bolster its...

Continue Reading
X4 Pharmaceuticals Completes Major Equity Financing and Leadership Shift

Updated Category News Views 178

Major Equity Financing by X4 Pharmaceuticals X4 Pharmaceuticals has made headlines recently with its announcement of a significant private equity financing round totaling $60 million. This funding is primarily geared towards advancing the company’s promising treatment for rare immune system diseases, demonstrating their commitment to improving patient outcomes. Leading...

Continue Reading
IGI Secures Fast Track from FDA for Promising Cancer Treatment

Updated Category News Views 124

IGI Receives Fast Track Designation for ISB 2001 Results from the dose-escalation portion of the Phase 1 clinical study of ISB 2001, an innovative treatment for heavily pretreated multiple myeloma patients, will be showcased at an upcoming major oncology conference. This exciting news highlights IGI's continued progress in developing groundbreaking therapies. About ISB...

Continue Reading
Prospera Energy Reports Strong Financial Performance for 2024

Updated Category News Views 163

Prospera Energy's Transformative Year: A Deep Dive into 2024 Financial Results In the recent strategic realignment, Prospera Energy Inc. (TSX.V: PEI, OTC: GXRFF) has successfully pivoted under new leadership, making significant strides in enhancing its production capabilities and financial outlook. This transformation was marked by key appointments, including Shubham Garg...

Continue Reading